Will symptomatic intracerebral hemorrhages decrease among eligible dabigatran-treated patients who receive intravenous tissue plasminogen activator for acute ischemic stroke?
Chan
Lung
L
D001562:Benzimidazoles / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy*; D002543:Cerebral Hemorrhage; D000069604:Dabigatran; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D001562:Benzimidazoles; D011725:Pyridines; D010959:Tissue Plasminogen Activator; D000069604:Dabigatran